Multinational study (n=2041) of first-line bevacizumab (Bev) plus taxane-based chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR/mBC): updated results of MO19391

被引：4

作者：

Cortes-Funes, H. ^{[1
]}

Pritchard, K. I. ^{[2
]}

Biganzoli, L. ^{[3
]}

Thomssen, C. ^{[4
]}

Pierga, J. ^{[5
]}

Koza, I. ^{[6
]}

Kwong, A. ^{[7
]}

Kellokumpu-Lehtinen, P. ^{[8
]}

Chlistalla, A. ^{[9
]}

Smith, I. ^{[10
,11
]}

机构：

[1] Univ Hosp 12 Octubre, Div Med Oncol, Madrid SW3 6JJ, Spain

[2] Univ Toronto, Dept Med, Sunnybrook Odette Canc Ctr, Fac Med, Toronto SW3 6JB, ON, Canada

[3] Hosp Prato, Ist Toscano Tumori, Med Oncol Unit, Prato, Italy

[4] Univ Halle Wittenberg, Univ Klin & Poliklin Gynaekol, Halle, Saale, Germany

[5] Univ Paris 05, Inst Curie, Paris, France

[6] Natl Canc Inst, Bratislava, Slovakia

[7] Univ Hong Kong, Queen Mary & Tung Wah Hosp, Div Breast Surg, Hong Kong, Hong Kong, Peoples R China

[8] Tampere Univ Hosp, Tampere, Finland

[9] F Hoffmann La Roche, Basel, Switzerland

[10] Royal Marsden Hosp, London, England

[11] Inst Canc Res, London, England

来源：

EJC SUPPLEMENTS | 2009年 / 7卷 / 02期

关键词：

D O I：

10.1016/S1359-6349(09)70909-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：265 / 266

页数：2